Neopterin and procalcitonin are suitable biomarkers for exclusion of severe Plasmodium falciparum disease at the initial clinical assessment of travellers with imported malaria by Witt, R. (René) te et al.
RESEARCH Open Access
Neopterin and procalcitonin are suitable
biomarkers for exclusion of severe Plasmodium
falciparum disease at the initial clinical
assessment of travellers with imported malaria
René te Witt1*, Marlies E van Wolfswinkel2, Pieter L Petit3, Jaap J van Hellemond1, Rob Koelewijn2,
Alex van Belkum1, Perry JJ van Genderen2
Abstract
Background: Most clinicians in developed, non-malaria endemic countries have limited or no experience in
making clinical assessments of malaria disease severity and subsequent decisions regarding the need for parenteral
therapy or high-level monitoring in febrile patients with imported malaria. In the present study, the diagnostic
accuracy of plasma soluble Triggering Receptor Expressed on Myeloid cells 1 (TREM-1), neopterin and procalcitonin
levels as biomarkers for severe Plasmodium falciparum disease was evaluated in 104 travellers with imported
malaria (26 patients with non-P. falciparum malaria, 64 patients with uncomplicated P. falciparum malaria and
14 patients with severe P. falciparum malaria).
Methods: TREM-1, neopterin and procalcitonin were determined in serum using commercially available ELISA or
EIA tests. The diagnostic performance of these biomarkers for severe disease was compared with plasma lactate, a
well-validated parameter for disease severity in patients with malaria, as reference. Severe malaria was defined
according to the modified WHO criteria.
Results: No significant differences in TREM-1 levels were detected between the different patient groups. Patients
with severe P. falciparum malaria had significantly higher neopterin and procalcitonin levels on admission when
compared to patients with uncomplicated P. falciparum malaria or non-P. falciparum malaria. Receiver Operating
Characteristic (ROC) curve analysis showed that neopterin had the highest Area-Under-the-ROC curve (AUROC 0.85)
compared with plasma lactate (AUROC 0.80) and procalcitonin (AUROC 0.78). At a cut-off point of 10.0 ng/ml,
neopterin had a positive and negative predictive value of 0.38 and 0.98 whereas procalcitonin, at a cut-off point of
0.9 ng/ml, had a positive and negative predictive value of 0.30 and 1.00.
Conclusion: Although the diagnostic value of neopterin and procalcitonin is limited, the high negative predictive
value of both neopterin and procalcitonin may be helpful for a rapid exclusion of severe malaria disease on
admission. This may be a valuable tool for physicians only occasionally dealing with ill-returned travellers from
malaria-endemic regions and who need to decide on subsequent oral anti-malarial treatment or timely referral to a
specialized centre for high-level monitoring and intensified parenteral treatment.
* Correspondence: r.tewitt@erasmusmc.nl
1Erasmus Medical Centre, Department of Medical Microbiology and
Infectious Diseases, ‘s Gravendijkwal 230, 3015 CE, Rotterdam, The
Netherlands
Full list of author information is available at the end of the article
te Witt et al. Malaria Journal 2010, 9:255
http://www.malariajournal.com/content/9/1/255
© 2010 te Witt et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Background
Travellers from industrialized countries and inhabitants
of malaria-endemic regions clearly represent two distinct
worlds of malaria [1]. The global burden of malaria is
largely carried by the world’s malaria-endemic regions
with as many as 500 million cases annually and a death
toll of 1 to 3 million children each year. Severe malaria
in areas of endemicity is associated with a mortality of
15 to 40% [2,3]. In many malaria-endemic regions, strict
triage for admission to ICU facilities must be applied
because the ICU capacity is usually limited. Recently, a
5-point Coma Acidosis Malaria (CAM) score based on
only acidosis (base deficit) and cerebral malaria (mea-
sured with Glasgow Coma Scale) was introduced, which
could identify adult patients with severe malaria who
were at high risk of death [4].
In striking contrast, in non-endemic industrialized
countries malaria is only seen as an occasionally
imported disease [5] and is usually associated with a low
case-fatality rate [6,7]. Even in the pre-artesunate era,
the mortality of severe malaria in non-endemic regions
was significantly lower when compared with regions of
malaria endemicity [6-8], probably reflecting the avail-
ability of adequate supportive care facilities in industria-
lized countries.
Industrialized countries, however, have to face other
-more trivial- problems. For instance, the expertise on
diagnosis and treatment of malaria is usually focussed in
some specialized hospitals and institutes but many ill-
returning travellers may present to non-specialized hos-
pitals or even general practitioners. Making a proper
diagnosis of malaria may be troublesome under these
circumstances, for instance, by lack of experience in the
examination of malaria thick and thin blood smears and
in the assessment of parasite load. These non-specialized
centres therefore often rely on rapid diagnostic tests for
the diagnosis of malaria [9]. Although sensitive in diag-
nosing P. falciparum malaria, these rapid tests do not
provide any information about the severity of the infec-
tion. Moreover, although artesunate, which is now con-
sidered the parenteral drug of choice for treatment of
severe falciparum malaria, is available as an orphan drug
in The Netherlands, it is currently only in stock in some
specialized centres but certainly not available in every
Dutch hospital. Some of these general hospitals do not
even have any drug in stock for the treatment of malaria
[10]. To prevent unnecessary delay in diagnosis of severe
malaria and institution of proper parenteral treatment, a
simple, well-validated, laboratory-based biomarker that
predicts or excludes severe disease accurately would be
of great help for those clinicians occasionally dealing
with febrile travellers returning from malaria endemic
regions. These clinicians have to decide on subsequent
oral anti-malarial treatment or a timely referral to a spe-
cialized centre for high-level monitoring and intensified
parenteral treatment. In the present study, the diagnos-
tic accuracy of plasma soluble Triggering Receptor
Expressed on Myeloid cells 1 (TREM-1), neopterin and
procalcitonin was evaluated as potential markers for
malaria disease severity in travellers with imported
malaria. These bio-substances are all involved in the sys-
temic pro-inflammatory response of the host to invading
pathogens. Some of these biomarkers are already in use
for the diagnosis and follow-up of sepsis or used in
treatment algorithms, resulting in a successful reduction
of antibiotic use and duration [11,12].
Methods
Study population
The Harbour Hospital is a 161-bed general hospital
located in Rotterdam. It also harbours the Institute for
Tropical Diseases, which serves as a national reference
centre. In the period 1999-2008 almost 500 cases of
imported malaria were diagnosed [13]. For the majority
of these cases, demographic, clinical and laboratory data
and serum samples were available. For the present
study, a representative sample of this cohort was taken
and analysed.
Definitions
Patients were classified as having severe P. falciparum
malaria if they met one or more of the WHO criteria
for severe malaria, as modified by Hien et al [14]:
• A score on the Glasgow Coma Scale of less then
11 (indicating cerebral malaria).
• Anaemia (haematocrit < 20%) with parasite counts
exceeding 100,000/μl (roughly corresponding to 2%
parasitaemia) on a peripheral blood smear.
• Jaundice (serum bilirubin > 50 μmol/l) with para-
site counts exceeding 100.000/μl on a peripheral
blood smear.
• Renal impairment (urine output < 400 ml/24 h and
serum creatinine > 250 μmol/l).
• Hypoglycaemia (blood glucose < 2.2 mmol/l).
• Hyperparasitaemia (> 10% parasitaemia).
• Systolic blood pressure < 80 mm Hg with cold
extremities (indicating shock).
Study design
In previous studies [6,13,15] these severity criteria were
also used to define severe malaria in non-immune
travellers. In the present study the occurrence of severe
malaria was considered a primary end-point. This
contrasts with the design of many studies in patients with
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severe malaria in regions of malaria endemicity where the
severity criteria are used as an entry criterion. In the
present study, plasma lactate was used as a surrogate para-
meter for acid-base dysbalance and reference biomarker. It
was evaluated in a previous study in non-immune travel-
lers with imported malaria [15]. The diagnostic perfor-
mance of TREM-1, procalcitonin and neopterin for
malaria disease severity was compared with that of plasma
lactate, which is routinely measured at the Institute
for Tropical Diseases in ill-returning travellers.
Procedures
On admission, blood samples were taken for analysis of
the red blood cell count, haematocrit, white blood cell
count, platelet count, serum electrolytes, total bilirubin,
serum creatinine, liver enzymes, and blood glucose. In
addition, a serum sample was taken on admission which
was stored at -20°C until analysis. For the determination
of plasma lactate, a separate blood sample was drawn on
admission without congestion and placed on melting ice
after which it was immediately analysed after isolation of
plasma. Malaria was diagnosed by QBC (Quantitative
Buffy Coat) analysis, by a rapid diagnostic antigen test for
malaria (Binax NOW® Malaria Test, Binax Inc., Maine,
USA) and by conventional microscopy of stained thick
and thin blood smears. In case of P. falciparum infec-
tions, parasite density was determined. When the parasi-
taemia was less than 0.5% infected erythrocytes, parasites
were counted per 100 leucocytes in thick smears. When
the parasitaemia was equal or higher than 0.5% infected
erythrocytes, infected erythrocytes were counted in thin
blood smear and expressed as a percentage of the total
erythrocytes. The number of parasites per microliter was
subsequently calculated from these data.
TREM-1 and neopterin levels were determined in serum
samples using commercially available ELISA tests (R&D
Systems, Abingdon, UK; DRG, Marburg, Germany, respec-
tively). Procalcitonin levels in serum samples were deter-
mined using a commercially available EIA test (VIDAS
BRAHMS Procalcitonin, bioMérieux, Lyon, France). All
tests were performed according to manufacturer’s instruc-
tions. Detection limits were 3.88 pg/ml for TREM-1,
0.2 ng/ml for neopterin and 0.05 ng/ml for procalcitonin,
respectively. According to the manufacturers, normal
serum values are < 100 pg/ml for TREM-1, < 3 ng/ml for
neopterin and < 0.1 ng/ml for procalcitonin.
Statistical methods
For comparison between groups, the Mann-Whitney
U-test was used and p-values of < 0.05 were considered
statistically significant. The diagnostic performance of
each biomarker was reported as sensitivity, specificity,
positive and negative predictive value for severe P. falci-
parum malaria and their corresponding 95% confidence
intervals. Of each test a Receiver Operating Characteris-
tic (ROC) curve, a graphical plot of sensitivity (true
positive rate) versus 1-specificity (false positive rate),
was constructed as a summary statistic and the area
under the ROC curve (AUROC) and its corresponding
95% confidence intervals were calculated. Youden’s
index J (J = sensitivity+specificity-1) was used to choose
the most appropriate cut-off point for each biomarker.
All statistical analyses were performed using SPSS 15.0.
Results
Patient characteristics
In total 104 travellers with imported malaria were
included in this study, of which 26 patients were diag-
nosed with a non-P. falciparum infection (Plasmodium
malariae n = 2; Plasmodium ovale n = 5; Plasmodium
vivax n = 19) and 78 patients were diagnosed with
P. falciparum infection. The general characteristics of all
patients are shown in Table 1.
Characteristics of patients with severe malaria
Thirteen patients fulfilled the criteria for severe malaria
at initial presentation. Another patient did not fulfil
these criteria on admission, but the clinical course dete-
riorated shortly hereafter with impaired consciousness
and hyperparasitaemia. Procalcitonin and neopterin
levels were already increased on admission in this parti-
cular patient. Eventually, at admission to the ICU, all
14 patients fulfilled one or more of the severity criteria
(GCS < 11, n = 1; anaemia with a parasite count exceed-
ing 100,000 trophozoites per μl, n = 2; icterus with a
parasite count exceeding 100,000 trophozoites per μl,
n = 8; acute oliguric renal insufficiency, n = 0; hypogly-
caemia, n = 0; hyperparasitaemia, n = 5 and shock, n =
1, respectively). Five patients had an impaired conscious
level but a GSC above 11; eight patients had a parasitae-
mia > 5%, respectively. The first arterial blood gas analy-
sis on ICU showed a median bicarbonate level of
22 mmol/l (range 17 to 26 mmol/l) and a median base
deficit of 2 (range -3 to 8). Median GCS was 15 (range
9 to 15). One patient needed mechanical ventilation.
Eleven patients received exchange transfusion as an
adjunct therapy. No case fatalities were observed. The
laboratory results on admission of travellers with
imported severe P. falciparum malaria were further
characterized by significantly lower platelet counts and
haemoglobin levels and by significantly higher plasma
lactate, bilirubin and C-reactive protein levels and
erythrocyte sedimentation rates, respectively (Table 1).
Analysis of biomarkers for severe malaria
TREM-1
No statistically significant differences were observed in
TREM-1 levels in serum, between patients with severe
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P. falciparum malaria, uncomplicated P. falciparum
malaria and non-P. falciparum malaria (Figure 1A).
Neopterin
Neopterin levels on admission were significantly higher
in travellers with severe P. falciparum malaria when
compared to travellers with uncomplicated P. falci-
parum malaria (p < 0.0001) and travellers with non-
P. falciparum malaria (p < 0.0001) (Figure 1B). ROC
curve analysis showed an AUROC of 0.85 (95% Confi-
dence Interval 0.76-0.94), suggesting a good accuracy
(Figure 2). As shown in Table 2, at a cut-off point of
10.0 ng/ml, neopterin had an excellent sensitivity and
negative predictive value but a poor specificity and posi-
tive predictive value for severe disease.
Procalcitonin
Procalcitonin levels were significantly higher in travellers
with severe P. falciparum malaria when compared to
travellers with uncomplicated P. falciparum malaria (p =
0.0022). However, no significant differences were noted
in comparison to travellers with non-P. falciparum
infections (p = 0.17) (Figure 1C). ROC curve analysis
showed an AUROC of 0.78 (95% CI 0.66-0.91), compati-
ble with a fair accuracy (Figure 2). At a cut-off point of
0.9 ng/ml, procalcitonin had an excellent sensitivity and
negative predictive value, whereas specificity and
positive predictive value for severe P. falciparum malaria
was poor (Table 2).
Plasma lactate
Plasma lactate levels were significantly higher in travel-
lers with severe P. falciparum malaria when compared
to travellers with uncomplicated P. falciparum malaria
(p = 0.0012) and travellers with non-P. falciparum
malaria (p = 0.0040). ROC curve analysis of plasma lac-
tate levels showed an AUROC of 0.80 (95% CI 0.65-
0.96) compatible with a good accuracy (Figure 2). At a
cut-off point of 1.8 mmol/l, lactate had an excellent
sensitivity and negative predictive value, but a poor spe-
cificity and positive predictive value for severe P. falci-
parum malaria (Table 2), respectively.
Combination of various biomarkers for severe falciparum
disease
Analysis of various combinations of newly tested bio-
markers and the use of different cut-off levels did not
result in better discrimination of patients with severe
P. falciparum malaria.
Discussion
Severe malaria is disreputable for its high case-fatality
rate, but the outcome of severe P. falciparum infec-
tions has significantly improved since the introduction
Table 1 General characteristics and laboratory results on admission of patients with various species of malaria. Data
are given as median (range)
Non-P. falciparum P. falciparum
Uncomplicated Severe
(n = 26) (n = 64) (n = 14)
Demographics
Male/female 20/6 51/13 6/8
Age, years 40 (17-62) 40 (11-67) 40 (26-57)
Continent of acquisition
Africa 12 (46%) 60 (94%) 12 (86%)
Asia 9 (35%) 3 (5%) 1 (7%)
South America 5 (19%) 1 (2%) 1 (7%)
Vital signs on admission
Body temperature, °C 38.8 (36.1-41.5) 38.7 (36.1-40.6) 38.8 (36.8-40.6)
Pulse rate, beats per minute 90 (60-130) 95 (68-120) 108 (78-140)
Systolic blood pressure, mm Hg 123 (100-196) 120 (95-185) 118 (80-160)
Laboratory data on admission
Parasite load, throphozoites/μl ND 5,502 (1.0-385,000) * 205,600 (80,500-860,000)
Plasma lactate, mmol/l 1.4 (0.7-3.0) * 1.5 (0.5-4.4) * 2.6 (0.9-5.8)
Haemoglobin, mmol/l 8.2 (6.1-10.1) 8.7 (5.3-11.1) * 7.6 (3.8-10.2)
Leucocytes, × 109/l 5.2 (1.9-9.3) 5.5 (1.8-11.3) 6.6 (3.2-18.5)
Platelets, × 109/l 93.0 (10.0-205.0) * 78.5 (16.0-247.0) * 27.0 (3.0-152.0)
C-reactive protein, mg/l 86.5 (18.0-208.0) * 109.0 (5.0-278.0) * 190.0 (91.0-265.0)
Serum creatinine, μmol/l 94.0 (66.0-149.0) 103.5 (63.0-208.0) 102.5 (70.0-199.0)
Total bilirubin, μmol/l 24.0 (6.0-84.0) * 25.0 (7.0-164.0) * 54.0 (20.0-269.0)
p-values as compared with severe P. falciparum malaria.
* indicates p < 0.01
ND, not done
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of artesunate as first line treatment of severe malaria,
in particular in developing countries [2]. In industria-
lized countries such as The Netherlands, the case-fatal-
ity rate of imported malaria is low and fatal cases are
only occasionally reported. In the present study, in
which the biomarkers TREM-1, neopterin and procal-
citonin were evaluated for their potential to be used as
a marker for severe malaria disease upon admission.
This contrasts with the design of many studies in
regions of malaria endemicity where severe malaria is
usually the entry criterion. For reasons of comparabil-
ity, the same set of criteria for severe malaria was
strictly applied for the diagnosis of severe malaria in
this study, even though the study population com-
prised of presumably non-immune travellers and some
authors even suggest a threshold of 5% in stead of 10%
parasitized erythrocytes to define hyperparasitaemia in
non-immune individuals.
Figure 1 Concentrations of potential biomarkers for disease severity in malaria patients on admission. Individual data are shown with
the median value of each biomarker; TREM-1 (panel A), neopterin (panel B), procalcitonin (panel C) and plasma lactate (panel D). Significant
differences in biomarker concentrations between patient groups (black square = non-P. falciparum malaria; black triangle up = uncomplicated P.
falciparum malaria; black triangle down = severe P. falciparum malaria) with P values < 0.0001 and < 0.005 are indicated by * and **, respectively.
te Witt et al. Malaria Journal 2010, 9:255
http://www.malariajournal.com/content/9/1/255
Page 5 of 8
Figure 2 Receiver Operating Curves (ROC) characteristics of the diagnostic performance of neopterin, procalcitonin and lactate for
severe P. falciparum malaria. The ROC curve is a graph of sensitivity (true positive fraction) plotted against 1-specificity (false positive fraction).
The performance of a diagnostic variable can be quantified by calculating the area under the ROC curve (AUROC). The ideal test would have an
AUROC of 1, whereas a random guess would have an AUROC of 0.5.
Table 2 Descriptive statistics of diagnostic accurary of neopterin, procalcitonin as compared with lactate for the
diagnosis of severe falciparum malaria on admission
Neopterin
95% Confidence Interval
Procalcitonin
95% Confidence Interval
Lactate
95% Confidence Interval
Optimal cut-off value 10 ng/ml 0.9 ng/ml 1.8 mmol/l
Youden’s index 0.60 0.53 0.58
Sensitivity 0.93 0.64-1.00 1.00 0.70-1.00 0.92 0.60-1.00
Specificity 0.67 0.54-0.78 0.53 0.40-0.66 0.66 0.51-0.78
Positive predictive value 0.38 0.23-0.56 0.30 0.17-0.47 0.39 0.22-0.59
Negative predictive value 0.98 0.86-1.00 1.00 0.87-1.00 0.97 0.83-1.00
The Youden’s index was used to choose an appropriate cut-off value.
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The quantification of soluble TREM-1 levels on
admission did not result in proper discrimination
of severe P. falciparum malaria from uncomplicated
P. falciparum malaria and non-P. falciparum malaria. In
contrast, travellers with severe P. falciparum malaria
had significantly higher levels of neopterin and procalci-
tonin on admission as compared with travellers with
uncomplicated P. falciparum malaria or non-P. falci-
parum malaria, respectively. These findings correspond
with the results of several other studies performed in
semi-immune malaria patients living in malaria-endemic
regions [16-18]. When the ROC curve characteristics of
neopterin and procalcitonin were compared to that of
plasma lactate, the AUROC of neopterin appeared
superior whereas the AUROC of procalcitonin appeared
inferior to that of lactate, suggesting that neopterin pro-
vided the most accurate diagnostic performance for
severe P. falciparum malaria in this cohort of travellers.
Unfortunately, the applicability of these tests in
the initial clinical assessment of patients with severe
P. falciparum malaria will probably be limited by the
poor positive predictive value of neopterin and procalci-
tonin indicating that neither test can serve as a valuable
tool for the diagnosis of severe P. falciparum malaria.
For illustration, applying a procalcitonin level > 0.9 ng/
ml or a neopterin level > 10.0 ng/ml as a guide to inten-
sified monitoring and treatment would result in more
than 20 of 64 patients with uncomplicated P. falciparum
malaria receiving more intensive monitoring and treat-
ment than strictly necessary. On the other hand, the
high negative predictive value of both neopterin and
procalcitonin suggests that these tests can still be of
value by providing a tool for exclusion of severe disease.
With either a procalcitonin level of less than 0.9 ng/ml
or a neopterin level of less than 7.9 ng/ml in serum on
admission as a cut-off point for severe P. falciparum
malaria, no patient with severe disease would have been
denied access to high-level monitoring and intensive
treatment. In a previous study, in which a semi-quanti-
tative ‘point-of-care’ procalcitonin test as a diagnostic
tool for severe P. falciparum malaria was evaluated pro-
spectively, all 6 patients with severe P. falciparum
malaria had procalcitonin values classified as either
“moderate” or “high” (corresponding to a procalcitonin
level ≥ 2 ng/ml), but never as “normal” or “low” [12].
This is compatible with the findings of the current ret-
rospective serum sample-based study in which procalci-
tonin was measured quantitatively.
Although severe or fatal malaria rarely results from
infections with the non-sequestering Plasmodium spe-
cies vivax, ovale and malariae, increased neopterin and
procalcitonin serum levels were also observed in the
majority of these patients, although levels were lower
than compared with severe P. falciparum malaria
patients. Although speculatively, these observations sug-
gest that the mechanism whereby neopterin and procal-
citonin levels increase in malaria, is not specific for
severe P. falciparum malaria alone. Therefore, it may
not accurately reflect the pivotal pathophysiological
events in complicated P. falciparum malaria, such as the
sequestration of infected red blood cells in the microcir-
culation of vital organs and disturbance of microcircula-
tory flow. Whereas an increased plasma lactate level
conceivably reflects a significant reduction in microcir-
culatory flow in vital organs, the elevated neopterin and
procalcitonin levels are probably the result of activation
of a common inflammatory host response evoked by
infection with the respective Plasmodium parasites. In
fact, some reports even suggest that P. falciparum
malaria per se is not associated with a stronger host
response than P. vivax or P. ovale malaria, but that the
parasite burden of the causative Plasmodium species
may also modulate the extent of the host inflammatory
response [19].
In conclusion, although neither neopterin nor procal-
citonin can probably serve as a useful single diagnostic
tool for severe P. falciparum malaria, the high negative
predictive value of both neopterin and procalcitonin
may be helpful for a rapid exclusion of severe P. falci-
parum malaria on admission. This may be a valuable
tool - particularly if available as a rapid diagnostic test -
for physicians only occasionally dealing with ill-returned
travellers and who need to decide on subsequent oral
anti-malarial treatment or a timely referral to a specia-
lized centre for high-level monitoring and intensified
parenteral treatment.
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